Effectiveness and Safety of Peritoneal Dialysis Treatment in Patients with Refractory Congestive Heart Failure due to Chronic Cardiorenal Syndrome
Table 3
Clinical and laboratory characteristics of study patients prior to and 6 months after PD.
Group A ()
Group B ()
Before
After
Before
After
Weight (kg)
62.4 ± 8.84
59.9 ± 7.82
64.6 ± 10.5
57.7 ± 9.57
ΔWeight (kg)
-
2.59 ± 1.15
-
6.93 ± 3.81##
SBP (mmHg)
114 ± 14.7
109 ± 9.38
159 ± 26.4
143 ± 20.7
DBP (mmHg)
66.1 ± 18.0
63.3 ± 8.44
89.2 ± 18.8
80.5 ± 16.9
Residual renal function (mL/min/1.73 m2)
25.0 ± 5.27
26.9 ± 5.39
14.1 ± 2.85
9.98 ± 3.31
Hemoglobin (g/L)
89.7 ± 12.0
102.7 ± 20.8
85.1 ± 12.4
103 ± 16.5
Albumin (g/L)
31.2 ± 3.07
27.6 ± 4.06
32.4 ± 4.59
32.9 ± 3.38
Urine output (mL/day)
865 ± 225
1021 ± 178
1010 ± 416
781 ± 357
Peritoneal ultrafiltration (mL/day)
-
198 ± 206
-
860 ± 306##
Dialysis dosage (L/day)
-
2 (2, 4)
-
6 (4, 8)##
NYHA class
II
0
5
0
13
III
5
2
8
5
IV
4
2
11
1
BNP (ng/mL)
2483 ± 1364
807 ± 498
3013 ± 1566
412 ± 238
LVEF (%)
24.6 ± 3.78
27.0 ± 6.12
32.0 ± 9.92
48.5 ± 4.32
Note. Compared with before ;; compared with group A . Data are expressed as numbers (percentage). SBP: systolic blood pressure; DBP: diastolic blood pressure; LVEF: left ventricular ejection fractions; BNP: B-type natriuretic peptide.
